Integra LifeSciences (IART) Beats Q2 Earnings and Revenue Estimates

Company Performance - Integra LifeSciences reported quarterly earnings of $0.45 per share, exceeding the Zacks Consensus Estimate of $0.43 per share, but down from $0.63 per share a year ago, indicating an earnings surprise of +4.65% [1] - The company posted revenues of $415.61 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 5.05%, although this represents a decline from year-ago revenues of $418.17 million [2] - Over the last four quarters, Integra has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times as well [2] Stock Performance - Integra shares have declined approximately 45.5% since the beginning of the year, contrasting with the S&P 500's gain of 8.2% [3] - The current Zacks Rank for Integra is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.59 on revenues of $419 million, and for the current fiscal year, it is $2.24 on revenues of $1.67 billion [7] - The outlook for the Medical - Instruments industry, to which Integra belongs, is currently in the bottom 40% of over 250 Zacks industries, which may impact the stock's performance [8]